2.Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy.
Young Min PARK ; Byung Hun BYUN ; Jong Young CHOI ; Si Hyun BAE ; Boo Sung KIM ; Hong Soeb SO ; Wang Shick RYU
Journal of Korean Medical Science 1999;14(2):165-170
To evaluate the clinical feasibility of the antibody titer against a chimeric polypeptide (named Core 518), in which a domain of Core and NS3 of hepatitis C virus (HCV) was fused, ELISA was performed in a total of 76 serum samples. Each serum was serially diluted using two-fold dilution method with distilled water into 10 concentrations. They were all positive for second generation anti-HCV assay (HCV EIA II; Abbott Laboratories). Genotyping RT-PCR, quantitative competitive RT-PCR, and RIBA (Lucky Confirm; LG Biotech) were also assayed. Anti-Core 518 antibody was detected in x 12800 or higher dilutions of sera from 35 of 43 chronic hepatitis C (81.4%) and nine of 16 hepatocellular carcinoma sera (56.3%), one of four cirrhosis (25%), 0 of four acute hepatitis C, and one of nine healthy isolated anti-HCV-positive subjects (p=0.0000). The anti-Core 518 antibody titers were well correlated with the presence of HCV RNA in serum (p=0.002). The anti-Core 518 antibody titers decreased significantly in nine of ten responders to IFN-alpha treatment. Monitoring anti-Core 518 titers may be helpful not only for differentiating the status of HCV infection among patients with various type C viral liver diseases, but also for predicting responses to IFN-alpha treatment.
Adult
;
Aged
;
Female
;
Genotype
;
Hepatitis C/immunology*
;
Hepatitis C/drug therapy*
;
Hepatitis C/diagnosis
;
Hepatitis C/blood
;
Hepatitis C Antibodies/immunology*
;
Hepatitis C Antibodies/blood
;
Hepatitis C Antigens/immunology*
;
Hepatitis C-Like Viruses/immunology*
;
Hepatitis C-Like Viruses/genetics
;
Human
;
Immunoblotting
;
Interferon Alfa-2a/therapeutic use*
;
Male
;
Middle Age
;
RNA, Viral/blood
;
Recombinant Fusion Proteins/immunology
;
Viral Core Proteins/immunology*
;
Viral Nonstructural Proteins/immunology*
3.Revision and update on clinical practice guideline for liver cirrhosis.
Ki Tae SUK ; Soon Koo BAIK ; Jung Hwan YOON ; Jae Youn CHEONG ; Yong Han PAIK ; Chang Hyeong LEE ; Young Seok KIM ; Jin Woo LEE ; Dong Joon KIM ; Sung Won CHO ; Seong Gyu HWANG ; Joo Hyun SOHN ; Moon Young KIM ; Young Bae KIM ; Jae Geun KIM ; Yong Kyun CHO ; Moon Seok CHOI ; Hyung Joon KIM ; Hyun Woong LEE ; Seung Up KIM ; Ja Kyung KIM ; Jin Young CHOI ; Dae Won JUN ; Won Young TAK ; Byung Seok LEE ; Byoung Kuk JANG ; Woo Jin CHUNG ; Hong Soo KIM ; Jae Young JANG ; Soung Won JEONG ; Sang Gyune KIM ; Oh Sang KWON ; Young Kul JUNG ; Won Hyeok CHOE ; June Sung LEE ; In Hee KIM ; Jae Jun SHIM ; Gab Jin CHEON ; Si Hyun BAE ; Yeon Seok SEO ; Dae Hee CHOI ; Se Jin JANG
The Korean Journal of Hepatology 2012;18(1):1-21
No abstract available.
Antiviral Agents/therapeutic use
;
Ascites/diagnosis/prevention & control/therapy
;
Cholagogues and Choleretics/therapeutic use
;
Fatty Liver/diagnosis/diet therapy
;
Fatty Liver, Alcoholic/diagnosis/drug therapy
;
Hemorrhage/prevention & control/therapy
;
Hepatic Encephalopathy/diagnosis/prevention & control/therapy
;
Hepatitis B, Chronic/diagnosis/drug therapy
;
Hepatitis C, Chronic/diagnosis/drug therapy
;
Humans
;
Liver Cirrhosis/*diagnosis/drug therapy/pathology/*therapy
;
Liver Cirrhosis, Biliary/drug therapy
;
Vasodilator Agents/therapeutic use
4.Occult Hepatitis B Virus Infection in Chronic Hepatitis C.
The Korean Journal of Gastroenterology 2013;62(3):154-159
Occult HBV infection is defined as the presence of HBV DNA in the liver (with or without detectable or undetectable HBV DNA in the serum) of individuals testing negative for HBsAg. Studies on occult HBV infection in hepatitis C patients have reported highly variable prevalence, because the prevalence of occult HBV infection varies depending on the hepatitis B risk factors and methodological approaches. The most reliable diagnostic approach for detecting occult HBV detection is through examination of liver DNA extracts. HCV has been suspected to strongly suppress HBV replication up to the point where it may be directly responsible for occult HBV infection development. However, more data are needed to arrive at a definitive conclusion regarding the role of HCV in inducing occult HBV infection. Occult HBV infection in chronic hepatitis C patients is a complex biological entity with possible relevant clinical implications. Influence of occult HBV infection on the clinical outcomes of chronic hepatitis C may be considered negative. However, recent studies have shown that occult HBV infection could be associated with the development of hepatocellular carcinoma and contribute to the worsening of the course of chronic liver disease over time in chronic hepatitis C patients. Nevertheless, the possible role of occult HBV infection in chronic hepatitis C is still unresolved and no firm conclusion has been made up until now. It still remains unclear how occult HBV infection affects the treatment of chronic hepatitis C. Therefore, in order to resolve current controversies and understand the pathogenic role and clinical impacts of occult HBV infection in chronic hepatitis C patients, well-designed clinical studies are needed.
Carcinoma, Hepatocellular/complications
;
DNA, Viral/analysis
;
Hepacivirus/genetics
;
Hepatitis B/*complications/*diagnosis/drug therapy
;
Hepatitis B virus/genetics
;
Hepatitis C, Chronic/*complications/*diagnosis/drug therapy
;
Humans
;
Interferon-alpha/therapeutic use
;
Liver/virology
;
Liver Neoplasms/complications
5.A Case of Acute Disseminated Encephalomyelitis Associated with Hepatitis C Virus Infection.
Jae Eun SIM ; Jun Bum LEE ; Yu Na CHO ; Sang Hyun SUH ; Ja Kyung KIM ; Kyung Yul LEE
Yonsei Medical Journal 2012;53(4):856-858
Acute disseminated encephalomyelitis (ADEM) is a monophasic autoimmune demyelinating disease of the central nervous system, which typically follows acute viral or bacterial infection or vaccination. We report a case of ADEM associated with hepatitis C virus (HCV) infection with positive serum and cerebrospinal fluid (CSF) anti-HCV antibody. After steroid treatment, neurologic symptoms were improved. Virus triggers autoimmunity or direct viral invasion plays a part in the genesis of ADEM. This is the first reported case of ADEM with anti-HCV antibody in the CSF.
Encephalomyelitis, Acute Disseminated/*diagnosis/drug therapy/etiology/virology
;
Female
;
Hepacivirus/pathogenicity
;
Hepatitis C/*complications
;
Humans
;
Methylprednisolone/therapeutic use
;
Middle Aged
6.Diagnostic value of novel hepatic fibrosis markers in assessing cirrhosis in patients with chronic hepatitis C.
Qian KANG ; Jian Xiang LIU ; Ning TAN ; Hong Yu CHEN ; Jia Li PAN ; Yi Fan HAN ; Xiao Yuan XU
Chinese Journal of Hepatology 2023;31(1):56-64
Objective: To investigate the efficacy of chitinase-3-like protein 1 (CHI3L1) and Golgi protein 73 (GP73) in the diagnosis of cirrhosis and the dynamic changes of CHI3L1 and GP73 after HCV clearance in patients with chronic hepatitis C (CHC) treated with direct-acting antiviral drugs (DAAs). The comparison of continuous variables of normal distribution were statistically analyzed by ANOVA and t-test. The comparison of continuous variables of non-normal distribution were statistically analyzed by rank sum test. The categorical variables were statistically analyzed by Fisher's exact test and χ(2) test. Correlation analysis was performed using Spearman correlation analysis. Methods: Data of 105 patients with CHC diagnosed from January 2017 to December 2019 were collected. The receiver operating characteristic curve (ROC curve) was plotted to study the efficacy of serum CHI3L1 and GP73 for the diagnosis of cirrhosis. Friedman test was used to compare CHI3L1 and GP73 change characteristics. Results: The areas under the ROC curve for CHI3L1 and GP73 in the diagnosis of cirrhosis at baseline were 0.939 and 0.839, respectively. Serum levels of CHI3L1 and GP73 in the DAAs group decreased significantly at the end of treatment compared with baseline [123.79 (60.25, 178.80) ng/ml vs. 118.20 (47.68, 151.36) ng/ml, P = 0.001; 105.73 (85.05, 130.69) ng/ml vs. 95.52 (69.52, 118.97) ng/ml, P = 0.001]. Serum CHI3L1 and GP73 in the pegylated interferon combined with ribavirin (PR) group were significantly lower at the end of 24 weeks of treatment than the baseline [89.15 (39.15, 149.74) ng/ml vs. 69.98 (20.52, 71.96) ng/ml, P < 0.05; 85.07 (60.07, 121) ng/ml vs. 54.17 (29.17, 78.65) ng/ml, P < 0.05]. Conclusion: CHI3L1 and GP73 are sensitive serological markers that can be used to monitor the fibrosis prognosis in CHC patients during treatment and after obtaining a sustained virological response. Serum CHI3L1 and GP73 levels in the DAAs group decreased earlier than those in the PR group, and the serum CHI3L1 levels in the untreated group increased compared with the baseline at about two years of follow-up.
Humans
;
Hepatitis C, Chronic/drug therapy*
;
Antiviral Agents/therapeutic use*
;
Membrane Proteins/metabolism*
;
Liver Cirrhosis/diagnosis*
;
Fibrosis
;
Biomarkers
8.Clinical features of 30 patients with cryoglobulinemia.
Xiao-Hu SHI ; Jie MA ; Chao LI ; Yu-Bing WEN ; Hang LI ; Ming-Xi LI ; Xue-Wang LI ; Xue-Mei LI
Acta Academiae Medicinae Sinicae 2014;36(6):639-644
OBJECTIVETo summarize the clinical features of cryoglobulinemia.
METHODWe retrospectively analyzed the clinical data of 30 patients admitted to Peking Union Medical College Hospital from January 2003 to March 2013 due to cryoglobulinemia.
RESULTSThe average age was(53.8±11.9)years in these 30 patients(12 men and 18 women),among whom 22 patient(73.3%)developed infectious diseases including hepatitis B(n=11)and hepatitis C(n=11);in addition,3 hepatitis B patients and 1 hepatitis C patient also had malignancies. Four patients(13.3%)were accompanied with malignant lymphocytic proliferation diseases,and three(10.0%)with connective tissue diseases. The cause of disease was unclear in 5 patients(16.7%). The clinical manifestations varied due to the primary diseases;notably,20 patients(66.7%)had an onset of purpura rash,22(73.3%)and 19(63.3%)were accompanied with hypertension and chronic renal insufficiency,respectively. The severity of renal involvement was relevant with the increase of C reactive protein,erythrocytes,sedimentation rate,and IgM and the decrease of complements. Treatment should be directed at the primary diseases. Glucocorticoid and immunosuppressants were good choices for relieving renal involvement. Elderly, type 1 cryoglobulinemia,and poor renal function were associated with the poor prognosis.
CONCLUSIONSCryoglobulinemia is mainly seen in middle and elderly patients. It can often affect multiple systems,in particular the kidney. Inflammatory markers,IgM,and complements is related with the disease severity. Age,primary disease,and renal function are related with prognosis.
Aged ; Cryoglobulinemia ; diagnosis ; drug therapy ; pathology ; Female ; Hepatitis C ; diagnosis ; Humans ; Immunosuppressive Agents ; therapeutic use ; Kidney ; pathology ; Male ; Middle Aged ; Prognosis ; Retrospective Studies
9.Clinical applications of transient elastography.
Clinical and Molecular Hepatology 2012;18(2):163-173
Chronic liver disease represents a major public health problem, accounting for significant morbidity and mortality worldwide. As prognosis and management depend mainly on the amount and progression of liver fibrosis, accurate quantification of liver fibrosis is essential for therapeutic decision-making and follow-up of chronic liver diseases. Even though liver biopsy is the gold standard for evaluation of liver fibrosis, non-invasive methods that could substitute for invasive procedures have been investigated during past decades. Transient elastography (TE, FibroScan(R)) is a novel non-invasive method for assessment of liver fibrosis with chronic liver disease. TE can be performed in the outpatient clinic with immediate results and excellent reproducibility. Its diagnostic accuracy for assessment of liver fibrosis has been demonstrated in patients with chronic viral hepatitis; as a result, unnecessary liver biopsy could be avoided in some patients. Moreover, due to its excellent patient acceptance, TE could be used for monitoring disease progression or predicting development of liver-related complications. This review aims at discussing the usefulness of TE in clinical practice.
Antiviral Agents/therapeutic use
;
Carcinoma, Hepatocellular/epidemiology/physiopathology
;
Chronic Disease
;
*Elasticity Imaging Techniques
;
Hepatitis B/drug therapy/physiopathology
;
Hepatitis C/drug therapy/physiopathology
;
Humans
;
Liver Cirrhosis/*diagnosis/ultrasonography
;
Liver Neoplasms/epidemiology/physiopathology
;
Recurrence
10.Hepatitis B and C Virus Infection and Liver Dysfunction in Patients Receiving Chemotherapy.
Chang Il KWON ; Ji Hyun LEE ; Ki Hyun CHOI ; Kwang Hyun KO ; Sung Pyo HONG ; Seong Gyu HWANG ; Pil Won PARK ; Doyeun OH ; Kyu Sung RIM ; Sehyun KIM
The Korean Journal of Gastroenterology 2006;48(6):408-414
BACKGROUND/AIMS: Liver dysfunction and reactivation of hepatitis virus are well-described complications in cancer patients who receive cytotoxic chemotherapy and may result in varying degrees of liver damage. However, there has been just few reports on such complications and on the preemptive use of lamivudine in Korea. The aims of this study were to determine the prevalence of hepatitis B and C virus infection and the incidence of liver dysfunction in patients with malignancies who receive chemotherapy, to determine the reactivation rate of hepatitis B virus (HBV) in those patients, to evaluate the effect of preemptive use of lamivudine in patients with HBV infection. METHODS: Among 1,477 patients who received chemotherapy due to various malignancies from January 2000 to June 2005, 668 patients with incomplete viral studies or hepatitis related malignancy were excluded. A retrospective study was conducted by reviewing the medical records of remaining 809 patients. RESULTS: The overall prevalence rate of hepatitis B or C virus in patients receiving chemotherapy was 6.55% (53/809). The incidences of liver dysfunction was not significantly different between hepatitis virus positive group and negative group. Reactivation rate of hepatiris B or C virus after chemotherapy was 15% (6/40). In all patients who received lamivudine therapy, aspartate aminotransferase and alanine aminotransferase level were normalized and HBV DNA negativity achieved. CONCLUSIONS: The existence of hepatitis virus in patients receiving chemotherapy did not significantly influence the development of severe liver dysfunction, owing probably to the lamivudine therapy. Further prospective studies are required to ascertain the reactivation of hepatitis virus in patients receiving chemotherapy and the need for prophylactic lamivudine therapy in HBV positive patients.
Adult
;
Antineoplastic Agents/*adverse effects
;
Antiviral Agents/*therapeutic use
;
Female
;
Hepatitis B/diagnosis/epidemiology/*prevention & control
;
Hepatitis C/diagnosis/epidemiology/*prevention & control
;
Humans
;
Lamivudine/*therapeutic use
;
Liver Diseases/chemically induced/*diagnosis/epidemiology
;
Male
;
Middle Aged
;
Neoplasms/complications/drug therapy
;
Prevalence